In this issue:
- Tucidinostat + R-CHOP in MYC/ BCL2 double-expressor DLBCL
- ctDNA assessment of response to lisocabtagene maraleucel vs. autologous SCT in LBCL
- ATLL: targeted maternal screening
- Tafasitamab-lenalidomide + R-CHOP as first line for high-risk DLBCL
- Adding autologous SCT to ibrutinib-containing first line regimen for mantle cell lymphoma
- All-oral treatment for newly diagnosed AML
- 28 vs. 14 days of venetoclax induction, with azacitidine, in older AML
- Identifying high-risk smouldering MM for early intervention
- Continuous or fixed-duration maintenance therapy in MM
- Donor-specific transplant outcomes
Please login below to download this issue (PDF)